Symbols

PAYS

Paysign·NASDAQ

--(--)

PAYS fundamentals

PAYS Q4 2025 Earnings

Paysign (PAYS) released its earnings on Mar 24, 2026: revenue was 22.76M (YoY +45.81%), beat estimates; EPS was 0.02 (YoY 0.00%), met estimates.

Revenue / YoY

22.76M

+45.81%

EPS / YoY

0.02

0.00%

Report date

Mar 24, 2026

PAYS Earnings Call Summary for Q4,2025

Exceptional Growth: 2025 revenue up 40.5% to $82 million, with pharma industry revenue tripling to $33.9 million. Operating margins expanded to 9%.
Patient Affordability Dominance: Saved clients $325 million in 2025 via dynamic business rules, with 131 active programs covering 6 top pharma companies.
2026 Outlook: $106.5-$110.5 million revenue target, 60%-62% gross margin, and nearly doubled net income ($13-$16 million).
Strategic Differentiation: AI-driven dynamic rules, payments expertise, and transparent pricing fend off competition and regulatory risks.

Earnings

EPS

Revenue

Revenue & Expenses

PAYS has released its 2025 Q3 earnings report, with revenue of 21.60M, reflecting a YoY change of 41.56%, and net profit of 2.22M, showing a YoY change of 54.17%. The Sankey diagram below clearly presents PAYS's revenue sources and cost distribution.

Key Indicators

Paysign (PAYS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Paysign (PAYS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Paysign (PAYS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Paysign (PAYS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown